Hunan Province Tumor Hospital
Clinical trials sponsored by Hunan Province Tumor Hospital, explained in plain language.
-
New combo targets tricky lung cancer transformation after standard therapy fails
Disease control Not yet recruitingThis study tests a combination of the targeted drug limertinib plus chemotherapy (carboplatin and etoposide) in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has transformed into small cell lung cancer after initial targeted therapy stopped working. About 30…
Phase: PHASE2 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug combo aims to shrink inoperable lung tumors enough for surgery
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, in 50 adults with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if the treatment can shrink tumors enough to allow surgery and improve survival. Part…
Phase: PHASE2 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Weight-Loss breakthrough for lung cancer patients?
Symptom relief Not yet recruitingThis study tests whether adding megestrol acetate (a drug that stimulates appetite) to standard first-line therapy helps malnourished non-small cell lung cancer patients gain weight. About 116 adults with advanced lung cancer will be randomly assigned to receive either standard t…
Phase: PHASE3 • Sponsor: Hunan Province Tumor Hospital • Aim: Symptom relief
Last updated May 26, 2026 11:48 UTC